Deucravacitinib (hydrochloride)

Overview

Deucravacitinib (BMS-986165) hydrochloride is an orally active allosteric inhibitor of tyrosine kinase 2 ( TYK2 ), with an IC 50 of 0.2 nM and a K i of 0.02 nM against the JH2 domain of TYK2 , and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib hydrochloride blocks IL-23 , IL-12 , p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib hydrochloride can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > STAT | Products > Signaling Pathways > IFNAR | Products > Signaling Pathways > JAK | Products > Signaling Pathways > Interleukin Related

Product Information

• Catalog No.: HY-117287A
• CAS No.: 1609392-28-0
• Molecular Formula: C20H20D3ClN8O3
• Molecular Weight: 461.92
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source